About US
Contact us
-
GSK launches bronchodilator treatment Incruse Ellipta in UKBritish drug-maker GlaxoSmithKline (GSK) has introduced a new once-daily bronchodilator treatment, Incruse Ellipta (umeclidinium) in the UK. A long-acting muscarinic antagonist (LAMA), Incruse has be2014/10/31
-
Johnson & Johnson unveils Asia Pacific Innovation Center in Shanghai, ChinaJohnson & Johnson Innovation has launched the Asia Pacific Innovation Center in Shanghai, China, with satellites in Singapore, Australia and Japan. The new centre will boost Johnson & Johnson2014/10/31
-
Merck’s Keytruda receives FDA breakthrough therapy designation to treat NSCLCMerck has received breakthrough therapy designation from US Food and Drug Administration (FDA) for its Keytruda (pembrolizumab) to treat patients with epidermal growth factor receptor (EGFR) mutation-2014/10/30
-
EU IMI launches new consortium to develop economic models for pharmaceutical industryA new European consortium Driving Reinvestment in research and development and Responsible Antibiotic Use (Drive AB) has been launched, to deal with the growing global threat of antibiotic resistance.2014/10/30
-
International Aspirin Foundation introduces two biennial awardsIn celebration of the 40th anniversary of the formation of The International Aspirin Foundation, we are delighted to announce the introduction of two biennial awards; a Senior Science Award and a Youn2014/10/30
-
Australia’s CSL to buy Novartis influenza vaccine business for $275mAustralia-based CSL has signed an agreement to acquire the global influenza vaccine business from Swiss drug-maker Novartis, for $275m. CSL will include the acquired business in its subsidiary bioCSL2014/10/29
-
Life science investment in Northern England: an interview with Dr Geoff Davison, CEO, BionowCurrently, what are the main challenges around investment in the biomedical and life science sectors across Northern England? There are a number of challenges, but primarily, it's access to funding.2014/10/29
-
EU IMI launches new consortium to develop economic models for pharmaceutical industryA new European consortium Driving Reinvestment in research and development and Responsible Antibiotic Use (Drive AB) has been launched, to deal with the growing global threat of antibiotic resistance.2014/10/29
-
Ipsen to market telotristat etiprate outside North America and JapanFrance-based Ipsen have entered an exclusive licensing agreement with US-based Lexicon Pharmaceuticals to market telotristat etiprate outside of North America and Japan. Lexicon will hold the rights2014/10/28
-
EMA committee recommends AstraZeneca’s Lynparza to treat ovarian cancerBritish-Swedish drug maker AstraZeneca has received positive feedback for its Lynparza (olaparib) from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). CHM2014/10/28